Navigation Links
SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
Date:3/13/2008

TSX symbol: SBS

CALGARY, March 13 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has been granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The patent has been issued to SemBioSys, which has exclusively licensed commercial rights associated with the patent to Botaneco Specialty Ingredients Inc. (Botaneco), its wholly owned subsidiary. The claims of European Patent EP0986309(B1) are broadly directed to the production of emulsions comprising oleosomes extracted from any living cell, including plants such as safflower, and the use of these emulsions in a wide range of commercial applications including food ingredient, personal care and over-the-counter as well as pharmaceutical applications.

"This patent demonstrates our commitment to diligently protect our proprietary oleosome technology. It provides broad coverage for the production of personal care, topical OTC and pharmaceutical, food and other products based on emulsions comprised of oleosomes in the European market," said Andrew Baum, President and CEO of SemBioSys. "The issuance of this patent further validates our leadership in the use of oilbodies in personal care and other topical applications. We plan to launch Hydresia(TM), Botaneco's first oleosome based ingredient, in Europe this spring after a successful launch in the U.S. and Canada last year."

Counterparts to the European patent EP0986309(B1) have issued in many jurisdictions worldwide including the United States, Canada, Australia, Japan, China, India and Mexico.

In September of 2007, Botaneco commissioned its new 10,000 square foot, state-of-the-art commercial manufacturing facility for the production of its all natural oleosome base emulsion for the personal care and cosmetic markets. Botaneco recently announced that its first international brand customer, Burt's Bees, launched three personal care products in the U.S. using Botaneco's Hydresia(TM) ingredient.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets.

About Botaneco (http://www.botaneco.ca)

From development through delivery, Botaneco manufactures and markets a branded line of ingredients that harness the naturally occurring benefits of protein protected seed oils. Botaneco provides performance, innovation and choice in creating natural, renewable and versatile delivery systems and ingredients used in the development of cosmetics, personal care and prescription topical/dermatology products beneficial to humans and the environment. Botaneco is a wholly-owned subsidiary of SemBioSys Genetics Inc.

About Hydresia(TM) (http://www.hydresia.com)

Hydresia(TM) is a base emulsion naturally derived from safflower seed oilbodies, or oleosomes, which can replace such traditional emulsifiers as petrolatum and animal byproducts in health and beauty products. Oleosomes serve as natural storehouses for the emollient oils, antioxidants and natural moisture barriers that help keep skin soft, supple and young looking. SemBioSys has developed a gentle and natural proprietary process to isolate oleosomes from the seed fully intact to provide lasting protection to the skin.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
2. SemBioSys signs option agreement for safflower-produced food ingredient
3. SemBioSys announces 2007 third quarter results
4. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
5. SemBioSys updates Apo AI development program
6. Jivan Awarded US Patent #7,340,349 for Splice Array Analysis
7. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
8. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
9. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
10. The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract
11. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 19, 2017 , ... As part ... webinars accessible to novices as well as experienced users, attendees will gain a ... coagulation screening tests. , Hemostasis testing quality is determined by preanalytical variables ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, 2017 /PRNewswire/ ... finance firm that provides senior debt to life ... closing of a $20 million senior secured term ... company engaged in the development and commercialization of ... orthopedic injuries. Cerapedics, lead product, i-FACTOR ...
(Date:4/18/2017)... Urdorf, Switzerland (PRWEB) , ... April 18, 2017 ... ... a smartphone/tablet app that converts conductivity readings to concentration levels and vice-versa. , ... analytical chemistry is analyzing solution strength in concentration control or monitoring. The principle ...
(Date:4/18/2017)... ... April 18, 2017 , ... Whitehouse Laboratories is ... MD&M East has helped take medical devices from concept to market by ... minds. , Whitehouse labs will showcase its diverse and comprehensive capabilities which are ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):